ChiCTR2300069057 版本V1.2 版本创建时间2025/04/27 16:56:53 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300069057 

最近更新日期:

Date of Last Refreshed on:

2023-07-06 21:29:53 

注册时间:

Date of Registration:

2023-03-06 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

中性粒细胞与淋巴细胞比值和带状疱疹痛转化相关性的队列研究

Public title:

Cohort study of the correlation between neutrophil to lymphocyte ratio and pain transformation in herpes zoster

注册题目简写:

English Acronym:

研究课题的正式科学名称:

中性粒细胞与淋巴细胞比值和带状疱疹痛转化相关性的队列研究

Scientific title:

Cohort study of the correlation between neutrophil to lymphocyte ratio and pain transformation in herpes zoster

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙文琴 

研究负责人:

孙文琴 

Applicant:

Sun Wenqin 

Study leader:

Sun Wenqin 

申请注册联系人电话:

Applicant telephone:

+86 158 7366 6967

研究负责人电话:

Study leader's telephone:

+86 158 7366 6967

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

15873666967@163.com

研究负责人电子邮件:

Study leader's E-mail:

15873666967@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖南省常德市人民路818号

研究负责人通讯地址:

湖南省常德市人民路818号

Applicant address:

818 Renmin Road, Changde, Hunan

Study leader's address:

818 Renmin Road, Changde, Hunan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

常德市第一人民医院

Applicant's institution:

The First People's Hospital of Changde City

研究负责人所在单位:

常德市第一人民医院

Affiliation of the Leader:

The First People's Hospital of Changde City

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

医-2023-002-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

常德市第一人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the First People's Hospital of Changde City

伦理委员会批准日期:

Date of approved by ethic committee:

2023-01-06 00:00:00

伦理委员会联系人:

周述香

Contact Name of the ethic committee:

Zhou Shuxiang

伦理委员会联系地址:

湖南省常德市人民路818号

Contact Address of the ethic committee:

818 Renmin Road, Changde, Hunan

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 13787875628

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

常德市第一人民医院

Primary sponsor:

The First People's Hospital of Changde City

研究实施负责(组长)单位地址:

湖南省常德市人民路818号

Primary sponsor's address:

818 Renmin Road, Changde, Hunan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南省

市(区县):

Country:

China

Province:

Hunan

City:

单位(医院):

常德市第一人民医院

具体地址:

湖南省常德市人民路818号

Institution
hospital:

The First People's Hospital of Changde City

Address:

818 Renmin Road, Changde, Hunan

经费或物资来源:

常德市第一人民医院

Source(s) of funding:

The First People's Hospital of Changde City

Target disease:

herpes zoster

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

研究NLR与带状疱疹痛转化的关系。  

Objectives of Study:

To study the relationship between NLR and pain transformation of herpes zoster.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.符合 《带状疱疹中国专家共识》带状疱疹诊断标准; 2.入院时处于急性期,发病时间≤ 7 d; 3.年龄> 18 岁,性别不限。

Inclusion criteria

1. Conform to the diagnostic criteria of herpes zoster in China Expert Consensus on Herpes Zoster; 2. The patients were in acute stage when they were admitted to hospital, and the onset time was <= 7 days; 3. Age > 18 years old, regardless of gender.

排除标准:

1.长期使用糖皮质激素、免疫抑制剂、免疫增强剂等药物; 2.伴有精神性疾病、认知功能障碍; 3.伴有严重免疫缺陷、传染性疾病、血液系统疾病等恶性肿瘤等疾病; 4.近期有急性感染; 5.妊娠、哺乳期女性。

Exclusion criteria:

1. Long-term use of glucocorticoids, immunosuppressants, immunopotentiators and other drugs; 2. Accompanied with mental disease and cognitive dysfunction; 3. Accompanied by severe immune deficiency, infectious diseases, hematological diseases and other malignant tumors; 4. Acute infection recently; 5. Pregnant and lactating women.

研究实施时间:

Study execute time:

From 2023-01-09 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-03-06 00:00:00 To 2023-05-31 00:00:00  

干预措施:

Interventions:

组别:

后遗神经痛组

样本量:

100

Group:

PHN

Sample size:

干预措施:

干预措施代码:

Intervention:

no

Intervention code:

组别:

非后遗神经痛

样本量:

100

Group:

Non PHN

Sample size:

干预措施:

干预措施代码:

Intervention:

no

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南省 

市(区县):

 

Country:

China 

Province:

Hunan 

City:

 

单位(医院):

常德市第一人民医院 

单位级别:

三甲 

Institution
hospital:

The First People's Hospital of Changde City

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

带状疱疹后神经痛的发生率

指标类型:

主要指标

Outcome:

Incidence of postherpetic neuralgia

Type:

Primary indicator

测量时间点:

测量方法:

量表

Measure time point of outcome:

Measure method:

指标中文名:

带状疱疹疼痛持续时间

指标类型:

次要指标

Outcome:

Duration of herpetic neuralgia

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中性粒细胞/白细胞比值

指标类型:

主要指标

Outcome:

Neutrophil/leukocyte ratio, NLR

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究是回顾性研究,未采用随机分配方法产生随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

This study is a retrospective study and did not use random assignment to generate random sequences.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

no

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-03-06 10:46:56